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Background: Carbapenem-resistant Gram-negative bacteria are recognized as a cause of difficult-to-treat infec-
tions associated with high mortality.
Objectives: To perform a systematic review of currently available data on distribution, characteristics and out-
come associated with carbapenem-resistant bloodstream infections in adult neutropenic patients.
Methods: Included studies were identified through Medline, Embase and Cochrane databases between January
1995 and April 2016. Random effect meta-analysis was used to quantify the association between carbapenem
resistance and mortality and between carbapenem exposure and resistance.
Results: A total of 30 studies from 21 countries were included. Overall carbapenem resistance varied from 2% to
53% (median 9%) among studies. Infections due to carbapenem-resistant Pseudomonas spp. were reported in
18 (60%) studies showing high median resistance rates (44% of all carbapenem-resistant Gram-negatives and
19% of Pseudomonas isolates). Resistance of Enterobacteriaceae was less commonly reported and bloodstream
infections due to carbapenem-resistant Klebsiella spp. were mainly documented from endemic areas (Greece,
Italy, Israel). Carbapenem resistance in Acinetobacter spp. was reported in 9 (30%) studies (median resistance
58% of Acinetobacter isolates). Mortality rates ranged from 33% to 71% (median 50%) in patients with
carbapenem-resistant infections. Carbapenem resistance appeared to correlate with mortality (OR 4.89, 95% CI
3.30–7.26) and previous exposure to carbapenems (OR 4.63, 95% CI 3.08–6.96).
Conclusions: Carbapenem resistance represents a threat to neutropenic patients. In this group, resistance is
likely promoted by previous carbapenem use and leads to high mortality rates. The knowledge of resistance pat-
terns is crucial and can direct clinicians in the use of alternatives to carbapenem-based regimens.
Introduction
Bloodstream infections (BSIs) are common among cancer patients,
showing prevalence rates ranging from 11% to 38% and crude
mortality rates up to 40%.1 In these patients, the excessive and
prolonged use of broad-spectrum antibiotics during febrile neutro-
penic episodes is a crucial factor for the colonization of various body
sites by MDR Gram-negative bacteria (GNB).2 The increasing preva-
lence of MDR GNB such as ESBL-producing organisms and
carbapenem-resistant (CR) bacteria has limited the choice of
effective antimicrobials, representing one of the biggest challenges
in treating immunocompromised patients in recent years.3
Carbapenems, in particular, often represent the last resort for
treating MDR GNB. Early use of a carbapenem (meropenem or imi-
penem/cilastatin) in febrile neutropenia is recommended for high-
risk patients (i.e. absolute neutrophil count<100 cells/mm3 for>7
days and/or significant comorbidities, or haemodynamically un-
stable patients), in case of previous infection or colonization with
ESBL-producing bacteria or in hospitals with high ESBL rates.4,5 As
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a consequence, the use of carbapenems in neutropenic patients
has greatly increased, likely contributing to the rise of CR infec-
tions. Furthermore, in this patient population an increase in infec-
tions caused by GNB, especially those prone to accumulate
multiple antibiotic resistances (e.g. Pseudomonas aeruginosa and
Acinetobacter baumannii), has been reported.6
A paucity of multicentre prospective studies on antimicrobial
resistance, however, currently limits the knowledge of carbape-
nem resistance prevalence and its impact on mortality among
neutropenic patients.
The aim of this systematic review was to examine currently
available data on the distribution, characteristics and outcome of
BSIs caused by CR GNB in adult neutropenic patients.
Methods
This study was conducted in accordance with the PRISMA guidelines as
described below.7
Search strategy and selection criteria
This review is registered with the PROSPERO international prospective
register of systematic reviews (CRD42016038278, www.crd.york.ac.uk/
PROSPERO/). We searched Medline, Embase and Cochrane databases for
publications in any language between 1995 and April 2016 documenting
carbapenem resistance in adult neutropenic patients with BSIs. All search
strings were discussed with a qualified librarian. Details of the bibliographic
search strategy are listed in Appendix S1 (available as Supplementary
data at JAC Online). Bibliographies of reviews and original publications
were hand searched for further studies. An additional search was per-
formed in Google Scholar with the same search criteria as that applied to
the electronic databases. We also searched BASE (Bielefeld Academic
Search Engine), ProQuest, ETHOS (Electronic Theses Online Service),
OpenDOAR and Clinical Key for conference proceedings, national reports,
open access material and abstracts that may not have been indexed in
these databases.
Data extraction
Any type of study, except case reports, was considered. Two investigators
(E. R. and A. M. P.) independently assessed each potentially relevant study
for eligibility. Disagreements were resolved by consultation with a third
party (P. N. A. H.). If eligibility could not be determined, the full article was
retrieved. Publications reporting original data on carbapenem resistance in
adult patients (18 years of age and older) with neutropenia and BSIs were
included. Bacterial isolates were considered resistant to carbapenems ac-
cording to the local interpretive criteria. A standardized data-extraction
method was used to record relevant features of each study into a database,
including: study characteristics (year of publication, recruitment time
period, country, study design, number of BSIs, bacteria cultured, reported
antibiotic susceptibilities), patient demographics (age, sex, definition and
duration of neutropenia, underlying disease), method of antimicrobial sus-
ceptibility testing and antimicrobial therapy. Outcomes assessed included
carbapenem resistance prevalence, previous carbapenem exposure as a
variable associated with carbapenem resistance, and mortality related to
CR infections. Studies that did not allow data retrieval on carbapenem re-
sistance in neutropenic patients or from BSIs, as well as paediatric studies,
were excluded.
Quality assessment
The Cochrane collaboration’s risk of bias tool was used to assess papers
for quality.8 Selection bias was assessed with the Critical Appraisal
Skills Programme (CASP) checklist for cohort and case–control studies
(www.casp-uk.net). Quality assessment charts were produced identify-
ing ‘good’, ‘adequate’ and ‘poor’ reporting (Appendix S2). Key quality
criteria for eligible studies included: a reliable measure of antibiotic
resistance, clear reporting of carbapenem resistance and BSIs. The same
quality indicators were applied for papers that included information on
mortality and previous carbapenem exposure. We intended to perform
adjustment for confounders of mortality (e.g. age, sex, comorbidities)
but only a few eligible studies reported patient-level data on these
characteristics.
Data analysis
Analyses were conducted using SPSS version 24.0 software (SPSS Inc.,
Chicago, IL, USA) and MetaXL version 5.0 (EpiGear International). Studies
comparing mortality and previous carbapenem exposure between CR and
carbapenem-susceptible (CS) bacteria were included in the meta-analysis.
The time to follow-up was taken as defined by each individual study and
30 day mortality was used as the primary outcome where several follow-
up times were reported.
ORs with 95% CI for mortality were calculated between CR and CS BSIs,
and ORs with 95% CI for carbapenem exposure as a variable associated
with carbapenem resistance were calculated between patients with CR and
CS infections or, in one study, between CR and other Gram-negative BSIs.
Because of the differences that were expected between studies, the results
were combined using a random effects model.9 Heterogeneity between
studies was assessed using the v2 (P<0.01 suggesting significant hetero-
geneity) and I2 tests (0%–40% no heterogeneity, 30%–60% moderate,
50%–90% substantial and 75%–100% considerable heterogeneity).10
Funnel plots were generated to explore the possibility of small study effects,
which can be caused by publication bias, and are reported in Appendix S3.
Results
Study characteristics
A total of 1699 citations were revealed by the literature searches.
From these, 185 articles were retrieved for further scrutiny and 30
met the inclusion criteria (Figure 1).11–40 Only one disagreement
concerning the study design occurred for a conference abstract
that was ultimately excluded from the review. No grey literature
or national reports were eligible for inclusion in the review. All
studies included were observational and most were retrospective
(Table 1). Twenty-eight reported information on prevalence of
carbapenem resistance among GNB; two articles did not analyse
CR prevalence but reported data on factors and/or outcome asso-
ciated with CR infections.11,22 Additional characteristics of the
included studies are reported in Appendix S4. Neutropenia was
defined by the majority of studies as an absolute neutrophil count
(ANC) below 500/mm3. Eight studies reported neutropenia as ANC
<1000/mm3 (with predicted decrease below 500 within
48–72 h),14,17–20 and two studies as ANC <1000/mm3.38,39
Duration of neutropenia was reported by nine stud-
ies.11,14,16,19,27,29,35,36,39 Haematological malignancies repre-
sented the main cause of neutropenia; seven studies included
also patients with solid cancer (ranging from 5% to 44% of the pa-
tient population). Acute leukaemia was the most common haem-
atological disease in 17 (57%) studies. The origin of BSIs was
nosocomial in the vast majority of cases (>90%). GNB BSIs ranged
from 22% to 74% (median rate 52%), while the number of GNB
among all isolates varied from 17% to 78% (median rate 51%).
GNB were more common than Gram-positive bacteria in 10 out of
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17 (59%) studies reporting GNB BSIs and in 13 out of 23 (57%) re-
porting the total number of GNB isolates. Escherichia coli
(35%, range 4%–61%), Klebsiella spp. (19%, range 0%–40%) and
Pseudomonas spp. (14%, range 0%–40%) were the most com-
mon isolated strains among GNB.
Antimicrobial susceptibility testing was documented according
to the CLSI in 16 studies12,14,17,18,22,23,25,28,31–33,35–38,40 and ac-
cording to EUCAST or to Swedish Reference Group for Antibiotics
(SRGA) breakpoints in two studies,11,21 while for the others the
testing method was not documented. Only two reports performed
molecular characterization of CR strains.11,32
Distribution of carbapenem resistance
Data were collected from various geographic areas: 16 studies
were conducted in Europe, North Africa and the Middle East, 10 in
Asia, 3 in Central and South America, and 1 in South Africa. As sum-
marized in Table 2, CR rates varied widely across the studies, rang-
ing from 2% to 33% (median 12%) among BSIs and from 2% to
53% (median 9%) among all GNB (data available from 14 and 25
studies, respectively). Figure 2 shows the pooled prevalence (or
single-study reported prevalence if n ¼ 1) of CR GNB bacteria by
country. The number of reports addressing the issue of CR GNB
increased over time, especially during the past decade. Only
5 papers were published between 1995 and 2005 compared with
11 during 2006–10 and 14 during 2011–16.
The prevalence of CR Pseudomonas spp. was reported in 18
(60%) studies and ranged from 6% to 100% (median 19%) among
Pseudomonas strains and from 11% to 100% (median 44%)
among all GNB. Carbapenem resistance >10% among isolated
Pseudomonas was reported in 14 out of 17 (82%) studies. Only
four recent studies, two from Italy, one from Turkey and one
from Israel, reported the occurrence of CR Klebsiella pneumoniae
(CR-Kp); resistance rates were 35%, 14%, 7% and 46% of all
Klebsiella spp. isolates, respectively (Table 2).13–15,30 CR was, in-
stead, less commonly reported among other Enterobacteriaceae
such as E. coli and Enterobacter spp. (Table 2). Nine (30%) studies
identified carbapenem resistance in Acinetobacter spp., highlight-
ing high median resistance rates (58%, range 13%–100% of all
Acinetobacter isolates).
Few studies reported resistance data for other antimicrobials
among GNB (Appendix S5). The majority of the studies highlighted
higher rates of resistance to antimicrobials often used as prophy-
laxis or empirical therapy (e.g. fluoroquinolones, piperacillin/tazo-
bactam and cephalosporins) compared with carbapenems
(Figure 3). A report from Turkey, however, documented higher
percentages of CR compared with ESBL-producing bacteria (23%
versus 15%, respectively).19 Compared with other GNB, P. aerugi-
nosa maintained consistently high levels of carbapenem resist-
ance (Figure 3). A Swedish study showed higher resistance rates
for imipenem compared with other antibiotics tested against
P. aeruginosa.21
Variables associated with the acquisition of
carbapenem resistance
Only a few studies analysed duration of neutropenia,40 disease
type or severity13,14 as factors associated with carbapenem
Records identified through
database searching
(n=1907)
Records screened after
duplicates removed
(n=1699)
Full text papers considered
(n=185)
Papers included in review
(n=30)
Duplicates (n=208)
Excluded on basis of title and abstract (n=1514)
Records excluded (n=155)
Studies reporting (n=30)
Prevalence of carbapenem resistance (n=28)
Resistance to carbapenem and other antibiotics (n=19)
Mortality associated with carbapenem resistance (n=10)
Association between previous carbapenem exposure and resistance (n=4)
Paediatric studies (n=233)
Not reporting BSIs (n=108)
Not reporting carbapenem reistance among
neutropenic patients (n=140)
Not reporting data in neutropenic patients (n=420)
Not reporting carbapenem resistance (n=625)
Not reporting carbapenem resistance in BSI (n=15)
Non-human studies (n=82)
Case reports and reviews (n=46)
Figure 1. Data search and extraction (PRISMA flow chart).
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resistance. In one study, salvage therapy and non-autologous
transplants were more frequent in CR compared with CS infec-
tions.13 Four studies reported previous exposure to carbapenems
as a variable associated with CR BSIs13,17,22,32 (Table 3), although
one study did not confirm the data in multivariate analysis.22 Our
meta-analysis showed an association between carbapenem re-
sistance and previous exposure to carbapenems (OR 4.63, 95% CI
3.08–6.96) (Figure 4).
Antimicrobial therapy and outcome of CR infections
One study out of 11 detailing the antimicrobial prophylaxis
received by neutropenic patients (Appendix S4) analysed the cor-
relation between prophylaxis and development of resistance but
did not evidence an increase in CR GNB.36 Empirical therapy
consisted mainly of piperacillin/tazobactam, cefoperazone/sulbac-
tam or an antipseudomonal cephalosporin with or without a
fluoroquinolone or an aminoglycoside. Carbapenems were used
as first-line empirical treatment in three studies and as escalation
therapy (e.g. in case of clinical deterioration, septic shock,
breakthrough BSIs) in nine. In one study, the combination of
piperacillin/tazobactam and colistin was identified as the preferred
empirical regimen due to high rates (>50%) of CR P. aeruginosa.27
Definitive treatment of CR BSIs was reported only in a few studies
and included colistin alone or in combination with amikacin or
rifampicin.11,13,19,22
Data on the outcome of CR BSIs in neutropenic patients were
reported by 10 studies.11,13,15–17,19,21,22,30,32 Mortality rates
ranged from 33.3% to 71.4% (median rates 50%). One study re-
porting only carbapenemase-producing Kp (KPC-Kp) BSIs
Table 1. Characteristics of included studies
Reference Period Country Study type
Number of
BSIs (GNB %)
GNB (% of
isolates)
E. coli,
Klebsiella spp.,
Pseudomonas
spp. (% of GNB)
Tofas et al.11 2010–14 Greece retrospective 50 (100) 50 (100) 0, 100, 0a
Alshukairi et al.12 2011–12 Saudi Arabia retrospective 75 (NR) 48/78 (62) 35, 23, 13
Andria et al.13 2008–14 Israel retrospective 423 (100) 100 33, 24, 20
Kara et al.14 2005–09 Turkey retrospective 536 (60) NR 33, 25, 13
Trecarichi et al.15 2009–12 Italy prospective 575 (46) 353/668 (53) 53, 12, 19
Kikuchi et al.16 2006–13 Japan retrospective 130 (24) 31/130 (24) 10, NR, 23
Moghnieh et al.17 2009–12 Lebanon retrospective 75 (57) 43/75 (57) 40, 26, 12
El-Mahallawy et al.18 2009 Egypt retrospective 39 (67) 26/39 (67) 4, 12, 19
Gedik et al.19 2010–12 Turkey retrospective 66 (74) 49/66 (74) 35, 27, 14
Kwon et al.20 2009–10 South Korea retrospective 222 (NR) 119/243 (49) 61, 26, 4
Kjellander et al.21 1995–2008 Sweden retrospective 667 (NR) 372/794 (47) 38, 21, 11
Mudau et al.22 2010–11 South Africa case–control 36 (100) NR NR, NR, 28
Huang et al.23 2003–05 Taiwan retrospective 275 (72) 263/340 (77) 22, 17, 14
Han et al.24 2008–10 China retrospective 75 (64) 47/94 (50) 47, 10, 0
Chen et al.25 2002–06 Taiwan retrospective NR 516/853 (60) 20, 17, 9
Jin et al.26 2008–09 Singapore prospective 49 (51) 25/49 (51) 44, 40, 12
Jeddi et al.27 2007 Tunisia prospective 27 (48) 13/27 (48) 8, 38, 8
Suarez et al.28 2005 Spain retrospective 12 (NR) NR 0, 0, 100b
Garnica et al.29 1995–2005 Brazil retrospective 123 (45) 56/123 (45) 23, 13, 27
Mikulska et al.30 2004–07 Italy retrospective 168 (32) 68/182 (37) 37, 10, 26
Irfan et al.31 1999–2006 India retrospective 1048 (NR) 442/1048 (42) 35, 12, 20
Kim et al.32 2001–05 South Korea case–control NR NR 0, 0, 100c
Baskaran et al.33 2004 Malaysia retrospective 50 (NR) 44/73 (60) 36, 26, 9
Oliveira et al.34 2004 Brazil prospective 91 (37) 59/118 (50) 17, 19, 22
Paul et al.35 1988–2004 Israel prospective 462 (55) 353/557 (63) 30, 17, 26
Solano et al.36 1999–2000 Spain case–control 41 (22) 9/54 (17) 56, 0, 0
Wang et al.37 1999–2002 Taiwan retrospective 371 (NR) 327/418 (78) 28, 19, 11
Fanci et al.38 1995–98 Italy retrospective 152 (56) 87/172 (51) 26, NR, 40
Gaytan-Martinez et al.39 1997 Mexico prospective 42 (52) 24/47 (51) 42,17, 8
Krcme´ry et al.40 1990–94 Slovak Republic retrospective 81 (NR) NR 0, 0, 100b
NR, not reported.
aOnly isolates of CR-Kp were included in the study.
bOnly Pseudomonas spp. isolates were considered in the study.
cOnly Acinetobacter spp. isolates were considered in the study.
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identified lower mortality in patients receiving combination ther-
apy with two or three active drugs compared with monotherapy
(38% and 33% versus 50%, respectively).11 Six studies compared
mortality in CR versus CS strains;13,15,17,19,21,32 among these, one
large study reported OR adjusted for confounders (e.g. demo-
graphic data, comorbidities, type of haematological disease).13
For these studies, our meta-analysis showed an association
between mortality and carbapenem resistance (OR 4.89, 95% CI
3.30–7.26) (Figure 5).
Meta-analyses
We performed sensitivity analyses excluding one study each time
and recalculating the combined results to investigate the influence
of an individual dataset on the pooled OR. For both meta-analyses,
the corresponding pooled ORs were not altered. ORs were also
consistent with the reported results when P. aeruginosa was
excluded from the analysis (OR 3.26, 95% CI 1.52–6.99); only recal-
culation for mortality and carbapenem resistance was possible for
this analysis due to the lack of patient-level data on carbapenem
use and carbapenem resistance (Appendix S6).
No heterogeneity was shown (Figures 4 and 5). To assess po-
tential publication bias, results from meta-analyses were assessed
using a funnel plot. Our funnel plots appeared asymmetrical
(Appendix S3), suggesting evidence of the omission of small stud-
ies showing no increase in mortality or association with carbape-
nem exposure to carbapenem resistance or other kinds of
statistical heterogeneity.
Discussion
A significant number of studies highlighting the emergence of car-
bapenem resistance among cancer patients have been published
during the past decade, while only a few reports between 1995
and 2005 addressed the issue of CR in cancer patients.41,42 In our
review, the number of reports documenting carbapenem resist-
ance increased considerably from 2005. High variability was shown
according to geographic location, with highest rates documented
in studies from south-eastern Europe, Israel and the Middle East.
Data from the Meropenem Yearly Susceptibility Test
Information Collection (MYSTIC) programme between 1997 and
2000 showed that carbapenems had nearly 100% susceptibility
among isolates from the neutropenic group.43 Recent surveillance
studies detailing the distribution of CR in patients with neutropenia,
however, are not currently available, limiting the knowledge of re-
sistance patterns in this patient population. Similarly, large studies
analysing risk factors for the development of CR in this patient
population are lacking. Although an association between disease
type or severity (AML, salvage therapy, non-autologous HSCT and
prolonged neutropenia) and carbapenem resistance has been
postulated, we could not confirm these data in our review due to
the paucity of studies analysing this correlation.13,22 As previously
documented, we observed a higher number of GNB BSIs compared
with Gram-positive BSIs.6
Consistent with other studies in cancer patients, our review re-
ports alarming rates of carbapenem resistance in Pseudomonas spp.,
even in areas with low rates of antimicrobial resistance such as
northern Europe.44,45 Acinetobacter spp. also showed high preva-
lence of antimicrobial resistance in neutropenic patients.25–31 Less
common were CR Enterobacteriaceae, documented mainly from
countries with high CR-Kp prevalence.11,13,15
Only two studies in our review analysed molecular mechanisms
of carbapenem resistance. The study of molecular patterns, how-
ever, can help to predict the type of resistances in a certain area or
identify the reason for different distributions of resistance among
pathogens. Increasing prevalences of KPC-Kp and metallo-b-lacta-
mase (MBL)-producing P. aeruginosa, for example, were reported in
various European and Mediterranean countries.46 KPC genes were
Asia and Middle East
China (n=1) 2%
Japan (n=1) 53%
India (n=1) 10%
Israel (n=2) 15%
Lebanon (n=1) 16%
Malaysia (n=1) 9%
South Korea (n=1) 4%
Singapore (n=1) 12%
Saudi Arabia (n=1) 15%
Taiwan (n=3) 6%
Egypt (n=1) 20%
Tunisia (n=1) 6%
Africa
Italy (n=3) 23%
Sweden (n=1) 2%
Spain (n=1) 11%
Turkey (n=2) 14%
Europe
Central and South America
Brazil (n=2) 7%
Mexico (n=1) 4%
Figure 2. Geographical distribution of carbapenem resistance prevalence (%) in GNB isolated from BSIs in neutropenic patients, with number of
included studies per country in parentheses.
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associated with TEM-, SHV- and CTX-M-15-producing strains among
CR Enterobacteriaceae while MBL genes (IMP and VIM) were present
in CR Acinetobacter spp. isolates.32,47 In our study, CR Klebsiella spp.
was limited to areas with high KPC-Kp rates, probably due to KPC
gene dissemination by plasmid spread which is common during
outbreaks in high-prevalence countries. Infections caused by CR in
Pseudomonas spp., instead, were reported in sites with relatively
low antibiotic resistance. This can be related to Pseudomonas efflux
system-based resistance that can be altered by exposure to various
antimicrobials (e.g. fluoroquinolones), resulting in accumulation of
resistance to multiple classes of antibiotics.48 We found that previ-
ous exposure to carbapenem was more frequently associated with
carbapenem resistance rather than carbapenem susceptibility.
While two studies reported the duration of exposure to carbape-
nems, none detailed antibiotic doses, limiting the evaluation of
dose–response effects.
The mortality rates for CR GNB infections found in our studies
are comparable to those of other reports.49,50 We identified, how-
ever, a higher risk of mortality associated with CR BSIs in neutro-
penic patients compared with CS infections. These data are yet to
Table 2. Distribution of CR isolates among the included studies
Reference
CR isolates CR Pseudomonas spp. CR Acinetobacter spp. CR Enterobacteriaceae
BSI (%) GNB (%)
Pseudomonas
spp. (%)
CR isolates
(%)
Acinetobacter
spp. (%)
CR isolates
(%)
Enterobacteriaceae
(%)
CR isolates
(%)
Alshukairi et al.12 NR 7/48 (15) NR NR NR NR NR NR
Andria et al.13 103/423 (24) 103/423 (24) 15/82 (18) 15/103 (15) 9/27 (33) 9/103 (9) Klebsiella spp. 46/101 (46) 46/103 (45)
E. coli 13/141 (9) 13/103 (13)
others 4/30 (13) 4/103 (4)
Kara et al.14 44/272 (16)a 44/272 (16) 5/36 (14) 5/44 (11) 22/38 (58) 22/44 (50) Klebsiella spp. 4/59 (7) 4/44 (9)
Trecarichi et al.15 72/263 (27) 72/353 (20) 47/66 (71) 47/72 (65) — — Klebsiella spp. 15/43 (35) 15/72 (21)
E. coli 3/187 (2) 3/72 (4)
Enterobacter spp. 2/26 (8) 2/72 (3)
Kikuchi et al.16 NR NR/NR (53) NR NR NR NR NR NR
Moghnieh et al.17 7/43 (16) 7/43 (16) 1/5 (20) 1/7 (14) 1/2 (50) 1/7 (14) Enterobacter spp. 3/17 (17) 3/7 (43)
El-Mahallawy et al.18 NR NR/NR (20) NR NR NR NR NR NR
Gedik et al.19 6/49 (12) 6/49 (12) 1/7 (14) 1/6 (17) 4/4 (100) 4/6 (67) Serratia marcescens 1/2 (50) 1/6 (17)
Kwon et al.20 NR 5/119 (4) 4/5 (80)b 4/5 (80) — — — —
Kjellander et al. 21 NR 6/372 (2) 5/42 (12) 5/6 (83) — — Enterobacter spp. 1/43 (2) 1/6 (17)
Mudau et al.22 NR NR 8/10 (80) NR NR NR NR NR
Huang et al.23 NR NR/NR (3) NR NR NR NR NR NR
Han et al.24 1/47 (2) 1/47 (2) — — 1/1 (100) 1/1 (100) — —
Chen et al.25 NR 11/516 (2) 4/47 (9) 4/11 (36) 7/54 (13) 7/11 (64) — —
Jin et al.26 3/25 (12) 3/25 (12) 3/3 (100)c 3/3 (100) — — — —
Jeddi et al.27 1/13 (8) 1/16 (6) NRd NR NR NR NR NR
Suarez et al.28 NR NR 2/12 (17) NR NR NR NR NR
Garnica et al.29 3/56 (5) 3/56 (5) NR NR NR NR NR NR
Mikulska et al.30 18/54 (33) 18/67 (27) 8/18 (44) 8/18 (44) — — Klebsiella spp. 1/7 (14) 1/18 (6)
Enterobacter spp. 1/7 (14) 1/18 (6)
Irfan et al.31 NR 42/442 (10) 8/86 (9) 8/42 (19) 34/58 (59) 34/42 (81) — —
Kim et al.32 NR NR NR NR 13/18 (72) NR NR NR
Baskaran et al.33 NR 4/44 (9) 1/4 (25) 1/4 (25) — — Enterobacter spp. 1/5 (20) 1/4 (25)
Oliveira et al.34 5/34 (15) 5/59 (8) 4/13 (31) 4/5 (80) 1/6 (17) 1/5 (20) — —
Paul et al.35 NR NR/NR (5)e NR NR NR NR NR NR
Solano et al.36 1/9 (11) 1/9 (11) NR NR NR NR NR NR
Wang et al.37 NR 19/327 (6) 19/327 (6) 19/19 (100) NR NR — —
Fanci et al.38 7/85 (8) 7/87 (8) 7/34 (21) 7/7 (100) — — — —
Gaytan-Martinez et al.9 1/21 (5) 1/24 (4) — — — — E. coli 1/10 (10) 1/1 (100)
Krcme´ry et al.40 NR NR 8/81 (10) NR NR NR NR NR
NR, not reported.
aPolymicrobial BSIs were not considered.
b3/4 imipenem resistant, 0/4 meropenem-resistant.
cOne strain became CR during therapy.
dHigh carbapenem resistance in P. aeruginosa reported (>50%, R. Jeddi, M. Achour, R. B. Amor, L. Aissaoui, W. Boutera^a, K. Kacem, R. B. Lakhal, H. B.
Abid, Z. BelHadjAli, A. Turki and B. Meddeb, unpublished results).
eIncrease from 5% to 15% after 15 days of hospitalization.
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be confirmed in large prospective studies and have often been
attributed to inadequate therapy.51
We are aware of several limitations of our study. First, the deter-
mination of prevalence and the results of the meta-analyses were
based on data mostly deriving from retrospective studies.
The availability of patient-level data was therefore limited, although
the largest study included in the meta-analysis adjusted data for
confounders of mortality. Second, even if the geographic distribu-
tion of carbapenem resistance in our study was comparable to that
reported for non-neutropenic populations, prevalence rates can
vary widely among different centres and may not be representative
of a country. Furthermore, centres with high rates of antibiotic re-
sistance are more likely to report carbapenem resistance data com-
pared with sites with lower resistance rates. This could have
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introduced a significant publication bias in our study. The method-
ology for determination of carbapenem resistance also varied
across studies and CR rates may have been underestimated by the
use of automated identification systems. Third, a selection bias
could have been introduced in the meta-analysis investigating the
correlation of carbapenem use with carbapenem resistance by the
use of control patients who had the antimicrobial-susceptible form
of the organism.52 Overall, these limitations highlight the need for
well-designed studies documenting the impact of CR in neutropenic
patients in order to provide useful information for the management
of BSI in this patient population.
Conclusions
To our knowledge, this is the first systematic review and meta-
analysis to explore the characteristics of carbapenem resistance in
neutropenic patients with BSIs.
The emergence of new resistance profiles affects patient
outcomes and impacts antimicrobial stewardship. Carbapenem re-
sistance, in particular, appears problematic for clinicians seeking an
adequate empirical therapy to treat cancer patients with severe in-
fections. Although carbapenems are frequently used as first-line
therapy in hospital settings with high rates of cephalosporin resist-
ance, their use could often be replaced by carbapenem-sparing regi-
mens that are still effective for treating ESBL-producing
organisms.53,54 In settings with significant presence of CR-producing
organisms, combinations of ‘old’ antimicrobials such as colistin, tige-
cycline and aminoglycosides (with or without a carbapenem) are
currently employed.55,56 Their use in empirical therapy, however,
can be associated with significant toxicity and further selection of re-
sistances, and needs to be supported by accurate laboratory detec-
tion of CR strains.57 In HSCT patients with febrile neutropenia at high
risk for CR-Kp infections (e.g. colonized with CR-Kp or during out-
breaks) empirical combination of at least two active agents against
Table 3. Factors associated with acquisition and outcome of CR BSIs
Reference
Characteristic
carbapenem resistance mortality
Tofas et al.11 NR multivariate analysis (14 day mortality):
• unresolved neutropenia (P¼0.006)
• septic shock (P¼0.04)
• monotherapy (P¼0.02)
Andria et al.13 univariate analysis: multivariate analysis (14 day mortality):
• salvage therapy,
non-autologous
transplant (P¼0.02)
• carbapenem resistance (P<0.001)
• high comorbidity, low functional capacity,
salvage therapy (P¼0.007)
• CR carrier status (P<0.001) • septic shock (P<0.001)
• Klebsiella spp. infections,
polymicrobic BSI (P¼0.07)
• polymicrobic BSI (P¼0.02)
• prolonged hospitalization,
low functional capacity (P<0.001)
• carbapenem treatment<30 days (P<0.001)
• inappropriate treatment (P<0.001)
Trecarichi et al. 15 NR 21 day mortality higher in CR-Kp compared
with CS K. pneumoniae (P¼0.04)
Moghnieh et al. 17 univariate analysis: univariate analysis:
• piperacillin/tazobactam and
carbapenem-based regimens>4 days (P¼0.05)
• carbapenem resistance correlated with death,
sepsis and intubation (P<0.001)
Gedik et al. 19 NR 30 day mortality higher in CR strains
Kjellander et al. 21 NR 30 day mortality higher in CR strains
Mudau et al.22 univariate analysis: NR
• metronidazole (P¼0.005)
and imipenem use (P¼0.001)
multivariate analysis:
• AML (P¼0.01), amikacin,
metronidazole use (P¼0.02)
Kim et al. 32 multivariate analysis higher in CR strains
• neutropenia (P¼0.039)
• carbapenem use >7 days (P¼0.030)
(for MBL strains, cephalosporin use>7 days)
NR, not reported.
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CR-Kp has been recommended.58 The impact of this approach on
patient outcomes, however, still needs to be demonstrated.
Given the likelihood that carbapenem use promotes CRE, anti-
biotic stewards need clear guidance about when alternatives to
carbapenems can be used. New compounds with demonstrated
efficacy against KPC-Kp, such as ceftazidime/avibactam, and CR
(but not MBL-producing) P. aeruginosa, such as ceftolozane/tazo-
bactam, are now available.58 Their efficacy in febrile neutropenia,
however, has not been validated.
The knowledge of patterns of resistance and specific factors
associated with CR BSIs remains essential for their management
among neutropenic patients. In this patient population,
carbapenem-sparing options still need to be defined in order to
limit the selection pressure for carbapenem resistance in GNB.
Large prospective studies investigating prevalence, risk factors and
outcome of CR infections in neutropenic patients are urgently
needed.
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